Core Viewpoint - The company reported significant growth in its mid-term performance for 2025, driven by new product launches and increased sales in its medical devices for stroke treatment [1] Financial Performance - The company achieved revenue of RMB 186 million, representing a year-on-year increase of 44.4% [1] - Gross profit reached RMB 127 million, up 53.9% year-on-year [1] - Net profit attributable to shareholders was RMB 50.94 million, marking a turnaround from a loss [1] Business Growth Drivers - The improvement in financial performance is primarily attributed to increased revenue from new hemorrhagic stroke treatment devices and rising sales of ischemic stroke treatment devices [1] - Sales of ischemic stroke treatment devices and other related devices increased by 38.3% and 29.2%, respectively [1] - Revenue from hemorrhagic stroke treatment devices increased by approximately RMB 37.7 million compared to the same period in 2024, largely due to the launch of new devices [1] Strategic Focus - The company is continuously upgrading its neurointerventional business to focus on differentiated treatment devices [1]
港股异动 | 心玮医疗-B(06609)涨超6% 上半年扭亏为盈赚5093.8万元